UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 695

Sortiert nach

Agranulocytosis after consumption of cocaine adulterated with levamisole

Annals of internal medicine, 2009-02, Vol.150 (4), p.287

2009

Volltextzugriff (PDF)

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes

Haematologica (Roma), 2023-02, Vol.108 (2), p.532

2023

Volltextzugriff (PDF)

Vaccine‐induced immune thrombotic thrombocytopenia presenting with normal platelet count

Research and practice in thrombosis and haemostasis, 2021-08, Vol.5 (6), p.e12596-n/a, Article e12596

2021

Volltextzugriff (PDF)

Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia

Harm reduction journal, 2009-11, Vol.6 (1), p.30-30

2009

Volltextzugriff (PDF)

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

HemaSphere, 2023-08, Vol.7 (S3), p.e551265b

2023

Volltextzugriff (PDF)

Unlucky bleeding: factor XIII

Minerva anestesiologica, 2022-03, Vol.88 (3), p.107

2022

Volltextzugriff (PDF)

Changing Frontline AML Treatment Patterns in Alberta, Canada from 2013 - 2022

Blood, 2022-11, Vol.140 (Supplement 1), p.11636-11637

2022

Volltextzugriff (PDF)

Survey of Red Cell Transfusion Patterns in Patients with Chronic Bone Marrow Failure Disorders in Northern Alberta, Canada

Blood, 2015-12, Vol.126 (23), p.4744-4744

2015

Volltextzugriff (PDF)

Facial dog bites treated at the Massachusetts General Hospital over a 20-year period

Oral surgery, oral medicine, oral pathology and oral radiology, 2020-08, Vol.130 (2), p.136-143

2020

Volltextzugriff (PDF)

Changing frontline AML treatment patterns from 2013 to 2022

Leukemia research, 2023-09, Vol.132, p.107354-107354, Article 107354

2023

Volltextzugriff (PDF)

Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS‐CAN prospective study

British journal of haematology, 2016-07, Vol.174 (1), p.88-101

2016

Volltextzugriff (PDF)

Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study

British journal of haematology, 2021-07, Vol.194 (2), p.319-324

2021

Volltextzugriff (PDF)

An evaluation of no‐treatment decisions in patients with newly diagnosed acute myeloid leukemia

American journal of hematology, 2021-01, Vol.96 (1), p.E17-E20

2021

Volltextzugriff (PDF)

Revised 15-item MDS-specific frailty scale maintains prognostic potential

Leukemia, 2020-12, Vol.34 (12), p.3434-3438

2020

Volltextzugriff (PDF)

Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study

Blood, 2020-11, Vol.136 (Supplement 1), p.41-43

2020

Volltextzugriff (PDF)

High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS

Blood, 2020-11, Vol.136 (Supplement 1), p.47-48

2020

Volltextzugriff (PDF)

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

Leukemia & lymphoma, 2022-11, Vol.63 (13), p.3165-3174

2022

Volltextzugriff (PDF)

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS

Leukemia research, 2018-11, Vol.74, p.21-41

2018

Volltextzugriff (PDF)

Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents

Blood, 2019-11, Vol.134 (Supplement_1), p.4245-4245

2019

Volltextzugriff (PDF)

1 – 25 von 695

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(636)
Mit Volltextzugriff
(652)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(453)
Life Sciences & Biomedicine
(371)
Humans
(277)
Female
(137)
Animals
(134)
Male
(128)
Mice
(85)
Biological And Medical Sciences
(84)
Middle Aged
(79)
Adult
(63)
Aged
(63)
Medical Sciences
(56)
Biochemistry & Molecular Biology
(48)
Physical Sciences
(47)
Science & Technology - Other Topics
(47)
Oncology
(45)
Multidisciplinary Sciences
(41)
Fundamental And Applied Biological Sciences. Psychology
(36)
Proteins
(36)
Neurosciences & Neurology
(34)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Agranulocytosis after consumption of cocaine adulterated with levamisole

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes

Vaccine‐induced immune thrombotic thrombocytopenia presenting with normal platelet count

Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES

Unlucky bleeding: factor XIII

Changing Frontline AML Treatment Patterns in Alberta, Canada from 2013 - 2022

Survey of Red Cell Transfusion Patterns in Patients with Chronic Bone Marrow Failure Disorders in Northern Alberta, Canada

Facial dog bites treated at the Massachusetts General Hospital over a 20-year period

Changing frontline AML treatment patterns from 2013 to 2022

Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS‐CAN prospective study

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an MDS‐CAN analysis

Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

An evaluation of no‐treatment decisions in patients with newly diagnosed acute myeloid leukemia

Revised 15-item MDS-specific frailty scale maintains prognostic potential

Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study

High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents

Suchergebnisse filtern